Reflow Medical Announces Enrollment Completion in the Wing-IT IDE CTO Clinical Trial

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CLI?src=hash" target="_blank"gt;#CLIlt;/agt;–Reflow
Medical, Inc. has announced the completion of enrollment in its Wing-IT
investigational device exemption trial, a prospective, multicenter,
nonrandomized study evaluating the ability of the Wingman catheter to
cross chronic total occlusions (CTOs) in peripheral lesions after failed
guidewire attempts.

Eighty-five patients with advanced peripheral artery disease enrolled in
the Wing-IT trial were evaluated at 12 centers in the U.S., Germany, and
Austria. John R. Laird, MD, of Adventist Heart and Vascular Institute,
St. Helena, California, is the principal investigator for the study.

“We would like to express our gratitude to the participating patients,
physician investigators, research staff and employees. Their efforts
have made it possible for us to reach this major milestone,” said Dr.
Laird.

The Wingman Crossing Catheter uses an extendable beveled tip that
creates a channel to help penetrate, or cross, the occlusion. This
enables further treatment of the lesion with therapeutic devices.

Isa Rizk, Chief Executive Officer of Reflow Medical, commented, “Our
goal is to expand the physician’s ability to treat CTOs, which often
develop in patients with advanced peripheral artery disease.
Facilitating CTO crossings helps physicians avoid amputations or bypass
surgery, which directly correlates to better long-term outcomes.”

About Reflow Medical, Inc.

Reflow Medical, Inc. is a private company focused on empowering
physicians through the design and development of innovative and
effective technologies for cardiovascular disease. Reflow is developing
a family of products to treat cardiovascular disease.

Contacts

Jennifer Carlyle
[email protected]
949-481-0399